Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TTY Biopharm Co's Total Liabilities for the quarter that ended in Mar. 2026 was NT$4,277 Mil.
TTY Biopharm Co's quarterly Total Liabilities
declined
from Sep. 2025 (NT$3,881.78 Mil) to Dec. 2025 (NT$3,296.73 Mil) but then
increased
from Dec. 2025 (NT$3,296.73 Mil) to Mar. 2026 (NT$4,277.19 Mil).
TTY Biopharm Co's annual Total Liabilities
declined
from Dec. 2023 (NT$3,368.77 Mil) to Dec. 2024 (NT$3,351.83 Mil) and
declined
from Dec. 2024 (NT$3,351.83 Mil) to Dec. 2025 (NT$3,296.73 Mil).
TTY Biopharm Co Total Liabilities Related Terms
TTY Biopharm Co Total Liabilities Historical Data
* Premium members only.
The historical data trend for TTY Biopharm Co's Total Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
TTY Biopharm Co's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Total Liabilities of NT$4,277 Mil mean?
TTY Biopharm Co (ROCO:4105) has a Total Liabilities of NT$4,277 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for TTY Biopharm Co and its competitors.
Is TTY Biopharm Co's Total Liabilities too high?
TTY Biopharm Co's current Total Liabilities is NT$4,277 Mil. Overall, TTY Biopharm Co has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TTY Biopharm Co's Total Liabilities compare to ZTS and UTHR?
TTY Biopharm Co's Total Liabilities of NT$4,277 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for TTY Biopharm Co and its competitors. TTY Biopharm Co's current Total Liabilities is NT$4,277 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TTY Biopharm Co stock overvalued right now?
Based on GuruFocus' analysis, TTY Biopharm Co (ROCO:4105) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$87.56, compared to a current price of NT$79.10 — trading 9.7% below its estimated fair value. The current Total Liabilities is NT$4,277 Mil. TTY Biopharm Co's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For TTY Biopharm Co (ROCO:4105), the current Total Liabilities is NT$4,277 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TTY Biopharm Co (ROCO:4105) Overvalued in 2026?
Based on GuruFocus' analysis, TTY Biopharm Co stock appears to be undervalued.
The current stock price of NT$79.10 is trading 9.7% below its estimated GF Value™ of NT$87.56.
GuruFocus considers TTY Biopharm Co to be Modestly Undervalued.
Key valuation signals for ROCO:4105:
Total Liabilities: NT$4,277 Mil
GF Value™: NT$87.56 vs. price of NT$79.10 (9.7% below fair value)
No single metric tells the full story. See the ROCO:4105 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TTY Biopharm Co Ltd is engaged in the manufacturing and marketing of pharmaceuticals and chemical drugs. The company's operating segments includes Oncology Business unit, Health Care Business unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business unit segment. It generates maximum revenue from the Oncology segment. Geographically, it derives a majority of revenue from Taiwan and also has a presence in America. Some of its products include Algitab, Alginos, Sulfin, Metacin, Cepiro, Brosym, Colimycin, Cubicin, and others.
83GF Score
Get the complete analysis for ROCO:4105
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4105 has been successfully added to your 
